Thanks. I was hoping to get a further breakdown of how many in each cohort responded. For that mid dose group to remain stable as the chart depicts, you have some that declined, some that improved and some that remained stable. Likewise for the high dose group. A small amount of very strong responders can cause a big change to that group.
Hopefully the peer review of the trial gives us those details if there is one in the works.
Market Data 
Markets 
AI
